Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival

KAYOKO TAKAHASHI1,2, YASUSHI SAGA1,2, HIROYUKI MIZUKAMI2, YUJI TAKEI1,2, SHIZUO MACHIDA1, HIROYUKI FUJIWARA1, KEIYA OZAWA2 and MITSUAKI SUZUKI1

1Department of Obstetrics and Gynecology, and 2Division of Genetic Therapeutics, Center for Molecular Medicine, School of Medicine, Jichi Medical University, Tochigi, Japan

Received April 27, 2009; Accepted June 25, 2009

DOI: 10.3892/ijo_00000385

Abstract. The purpose of this study was to explore the possibility of molecular-targeted therapy with anti-epidermal growth factor receptor (EGFR) antibody (cetuximab) for endometrial cancer to develop a new treatment for advanced endometrial cancer. We analyzed EGFR protein expression and gene mutations in the human endometrial cancer cell line HEC1A, and evaluated the in vitro and in vivo effects of cetuximab on HEC1A. EGFR expression was observed in HEC1A cells, but no mutations in the EGFR gene were detected. Cetuximab inhibited HEC1A cell growth and invasion and VEGF-A production in vitro, and HEC1A cell tumor growth, its peritoneal dissemination with ascites, and lymph node and lung metastasis in vivo. In addition, the antibody prolonged the survival of a mouse model of systemic metastasis. These results suggest the possibility of molecular-targeted therapy using cetuximab for endometrial cancer.

Introduction

Endometrial cancer is the most commonly encountered gynecologic malignancy and the fourth most common of all malignant tumors in the United States (1). Since this cancer is often detected at an early stage when it is localized to the uterus, the overall survival rate exceeds 80% (1). However, the prognosis of advanced endometrial cancer remains poor (2). In addition to surgery, radiotherapy and multidrug chemotherapy have been attempted for advanced endometrial cancer, but no satisfactory results have been achieved. As a result, the overall treatment results in endometrial cancer have not improved over the past 30 years (1). The most important prognostic factor for endometrial cancer is the presence or absence of extratumoral extension, including lymph node and lung metastasis, serosal invasion, and omental metastasis (3,4). Therefore, to improve the prognosis of endometrial cancer, it is necessary to develop an effective therapy for such advanced cancers.

Epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) are reportedly involved in the growth and extension of malignant tumors (5). In particular, EGFR overexpression has been observed in various malignant tumors: in 40-80, 14-91, 33-74, 25-77, 30-50, 40-80, 50-90, and 36-100% of lung, breast, stomach, colon, pancreas, prostate, kidney and head and neck cancers, respectively (6). Further, EGFR overexpression has been reported to be a poor prognostic factor for various malignant tumors (7,8). It has been reported that EGFR is expressed in 67% of endometrial cancers, and correlated with the disease stage, myometrial invasion, and lymph node metastasis (9).

Cetuximab, an anti-EGFR monoclonal antibody, is a molecular-targeted therapeutic agent that was produced as a human-mouse chimeric antibody, has a higher binding affinity for EGFR than natural ligands and inhibits tyrosine kinase phosphorylation (10,11). In addition, cetuximab reportedly induces EGFR internalization and degradation (12). The purpose of this study was to explore the possibility of molecular-targeted therapy using anti-EGFR antibody (cetuximab) for endometrial cancer to develop a new treatment for advanced endometrial cancer.

Materials and methods

Cell culture. The human endometrial cancer cell line HEC1A (13) was kindly provided by Dr H. Kuramoto, Kitasato University. This cell line was cultured in Dulbecco's modified Eagle's medium/F12 (DMEM/F12, Gibco, Grand Island, NY) supplemented with 10% inactivated fetal calf serum, 100 U/ml of penicillin and 100 μg/ml of streptomycin (Gibco) at 37°C in a 5% CO₂ atmosphere.
**EGFR expression.** EGFR expression in the HEC1A cell line was analyzed by Western blotting using anti-EGFR polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).

**EGFR gene mutations.** The HEC1A cell line was analyzed for EGFR gene mutations. Genomic DNA was extracted from the HEC1A cell line using a QIAamp DNA mini kit (Qiagen, Valencia, CA). The hot spots (exons 18-21) of EGFR gene mutations were amplified by PCR using EX Taq (Takara, Tokyo, Japan) and primers (5’-tacacccagtggagaagtcc-3’ and 5’-cccaacacagcagcttc-3’ for exon 18, 5’-caattgccagttaacgtcttcc-3’ and 5’-ggagatgagcagggtctagag-3’ for exon 19, 5’-cacactgacgtgcctctc-3’ and 5’-cttatctcccctccccgta-3’ for exon 20, and 5’-agggcatgaactacttg-3’ and 5’-cctccttctttgcctccttc-3’ for exon 21) under the following cycling conditions: for exons 18 and 19, 30 cycles of 94°C for 30 sec, 58°C for 30 sec, and 72°C for 1 min; for exon 20, 30 cycles of 94°C for 30 sec, 56°C for 30 sec, and 72°C for 1 min; and for exon 21, 35 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min. PCR products were separated by 0.8% agarose gel electrophoresis, purified, inserted into the pGEM-T easy vector (Promega, Madison, WI), and sequenced to confirm the presence or absence of mutations.

**Anti-EGFR monoclonal antibody (cetuximab).** Cetuximab was purchased from iRxMedicine Inc. (Tokyo, Japan), and used undiluted at a concentration of 2 mg/ml in all animal model experiments.

**Effects of cetuximab in vitro.** In all in vitro experiments, HEC1A cells were cultured in DMEM/F12 medium supplemented with 50 μg/ml EGF (R&D Systems, Minneapolis, MN) but not with fetal calf serum, and exposed to cetuximab at concentrations of 0-100 μg/ml.

To examine the inhibitory effect of cetuximab on cell growth, 5,000 HEC1A cells were dispensed into the wells of 96-well plates. After 48 h, reagents in the XTT assay Kit (Roche, Indianapolis, MA) were added, and the absorbance was measured after 24 h.

To investigate the inhibitory effect of cetuximab on cell invasion, 10,000 HEC1A cells/well were plated in Matrigel invasion chambers (Becton-Dickinson, Bedford, MA). After 24 h, cells invading through the membrane were stained with crystal violet to count the number of invading cells per 4 high-power fields.

To evaluate the effect of cetuximab on VEGF-A production, 5,000 HEC1A cells/well were placed in 96-well culture dishes. After 48 h, the concentration of VEGF-A in the culture supernatant was determined using a Quantikine Human VEGF ELISA Kit (R&D Systems).

**Animal model experiments.** Female 4- to 6-weeks-old nude mice (BALB/c nu, Japan Clea Laboratories, Tokyo, Japan) were used for experiments. All animal experiments were performed according to the guidelines for animal experimentation of Jichi Medical University.

To create a subcutaneous tumor model, 5x10^6 HEC1A cells were injected subcutaneously to form subcutaneous tumors. The tumor volume [(long diameter) x (short diameter)^2 x 0.5] was measured weekly to construct tumor growth curves.

To generate a peritoneal dissemination model, 5x10^6 tumor cells were injected intraperitoneally into nude mice, and the number of peritoneal disseminations and volume of ascetic fluid were measured after 8 weeks.

To develop a lymph node metastasis model, 5x10^6 tumor cells were injected into the uterine cavity of nembutal-anesthetized, laparotomized mice, and the number of enlarged lymph nodes was counted after 8 weeks.

To develop a lung metastasis model, 5x10^6 tumor cells were injected into the tail vein of nude mice, and the number of lung metastases was counted after 8 weeks.

To generate a systemic metastasis model, 5x10^6 tumor cells were injected into the peritoneal cavity and tail vein of nude mice, and the mice were observed until death. Survival curves were constructed by the Kaplan-Meier method.

In each experimental model of endometrial cancer, 1 mg of cetuximab was injected intraperitoneally twice weekly. An equal volume of phosphate-buffered saline (PBS) was used as a control.

**Statistical analysis.** Except for Kaplan-Meier survival curves, all differences between two groups were tested for significance by Student’s t-test. Differences in Kaplan-Meier survival curves were evaluated by the log-rank test. P<0.05 was considered significant.
Results

EGFR expression. As shown in Fig. 1, EGFR expression was detected by Western blotting at the position corresponding to a molecular weight of 170 kDa in HEC1A cells.

EGFR gene mutations. No mutations in exons 18-21 of the EGFR gene were detected in HEC1A cells.

Effects of cetuximab in vitro. Analysis of the inhibitory effect on cell growth showed that the number of cells 48 h after exposure was significantly smaller in the groups exposed to cetuximab at 0.01 μg/ml or higher than in the control group (P<0.05), indicating that cetuximab inhibited HEC1A cell growth (Fig. 2).

In the analysis of the inhibitory effect on cell invasion, the number of invading cells was significantly smaller in the groups exposed to cetuximab at 0.1 μg/ml or higher than in the control group (P<0.05), indicating that cetuximab inhibited HEC1A cell invasion (Fig. 3).

In the analysis of the inhibitory effect on VEGF-A production, the concentration of VEGF-A in the culture supernatant was significantly lower in the groups exposed to cetuximab at 0.01 μg/ml or higher than in the control group (P<0.05), indicating that cetuximab inhibited VEGF-A production (Fig. 4).

Animal model experiments. In the subcutaneous tumor model, tumor growth was significantly reduced from 3 weeks after inoculation in the cetuximab-administered group in comparison with the control group (Fig. 5), indicating that cetuximab inhibited HEC1A tumor growth.

In the peritoneal dissemination model, the number of peritoneal disseminations and volume of ascitic fluid 8 weeks after inoculation were significantly smaller in the cetuximab-administered group, at 3.7±2.1 and 0.2±0.1 ml, respectively, than in the control group (17.5±6.2 and 4.3±5.4 ml, respectively (P<0.01 and 0.05, respectively), indicating that cetuximab inhibited the dissemination of HEC1A tumors and production of ascitic fluid (Figs. 6A, B, C and D).

In the lymph node metastasis model, the mean number of enlarged lymph nodes in the cetuximab-administered group 8 weeks after inoculation was 0.25±0.5, which was significantly smaller than that (2.0±0.0) in the control group (P<0.01), indicating that cetuximab inhibited the lymph node metastasis of HEC1A cells (Figs. 6E and F).

In the lung metastasis model, the mean number of lung metastases 8 weeks after inoculation was 3.7±0.6 in the control group, but no lung metastases were observed in the cetuximab-administered group, indicating that cetuximab inhibited the lung metastasis of the HEC1A cells (Figs. 6G and H).

Fig. 7 shows survival curves for the cetuximab-administered and control groups in the systemic metastasis model. In the control group, the mice began to die from the 48th day after cancer cell injection, and all had died on the 62nd day. In contrast, in the cetuximab-administered group, only two mice died, showing a significantly longer survival (P<0.01). Thus, cetuximab prolonged the survival of the mouse systemic metastasis model.

Discussion

In this study, we explored the possibility of molecular-targeted therapy using anti-EGFR antibody (cetuximab) for endometrial cancer to develop a new treatment for advanced endometrial cancer.
As a result, cetuximab inhibited HEC1A cell growth and invasion and VEGF-A production in vitro, and HEC1A-cell tumor growth, peritoneal dissemination with ascites, and lymph node and lung metastasis in vivo. In addition, the antibody prolonged the survival of a mouse model of systemic metastasis.

Cetuximab is an anti-EGFR monoclonal antibody binding to EGFR to inhibit its activity, and it is a molecular-targeted therapeutic agent against specific molecules involved in tumor growth. It is a human-mouse chimeric antibody of the IgG1 subclass, and is clinically administered as an intravenous infusion. Currently, cetuximab has been approved by the Food and Drug Agency (FDA) as a therapeutic agent for metastatic colorectal cancer (14) and head and neck cancer (15), and used clinically.

On the other hand, there have been no reports on molecular-targeted therapy using cetuximab for endometrial cancer. The report that endometrial cancer frequently overexpresses the cetuximab-targeted EGFR (9) suggested that cetuximab would be useful in the treatment of endometrial cancer, and led to this study. As a result, cetuximab inhibited HEC1A cell growth and invasion and VEGF-A production in vitro, and HEC1A cell tumor growth, peritoneal dissemination with ascites, and lymph node and lung metastasis in vivo. In addition, the antibody prolonged the survival of a mouse model of systemic metastasis. These results suggest the possibility of molecular-targeted therapy using cetuximab for endometrial cancer.

EGFR is composed of three major domains: extracellular, transmembrane, and intracellular domains. When ligands such as EGF bind to the extracellular domain, EGFR-ligand complexes bind to other receptors to form dimers, and then the tyrosine kinase region in the intracellular domain utilizes adenosine triphosphate to phosphorylate tyrosine residues. Tyrosine phosphorylation results in the activation of intracellular signal transduction pathways, leading to the promotion of cell growth and invasion (16). EGFR was expressed in the endometrial cancer cell line HEC1A used in this study, and EGF addition promoted cell growth in vitro. These results suggest that cetuximab blocked the binding of EGF to EGFR, thereby inhibiting endometrial cancer cell growth and invasion.

On the other hand, in malignant tumors such as non-small cell lung cancer, it has been reported that mutations occur in EGFR gene exons 18-21 coding for the intracellular domain, resulting in the constitutive activation of EGFR, which is involved in malignant cell transformation (17). Currently, gefitinib (18,19) and erlotinib (20), which are molecular-targeting drugs specifically inhibiting EGFR tyrosine kinase activity, are reportedly effective against cancers with EGFR gene mutations. However, no such mutations were detected in the endometrial cancer cell line HEC1A used, and cetuximab was effective. Further, there have been no reports of patients with endometrial cancer with EGFR gene mutations. Therefore, it is very likely that cetuximab is effective for many patients with endometrial cancer.

Cetuximab inhibited VEGF-A production in HEC1A cells, as already reported in bladder (21) and colorectal (22) cancer cells. A study in head and neck cancer cells (23) reported that the inhibition of VEGF-A production by cetuximab was mediated by EGFR. On the other hand, Luwor et al reported that the inhibitory effect of cetuximab on VEGF-A production was mediated by hypoxia-inducible factor-1 alpha (HIF-1alpha) (24). Angiogenesis is closely involved in the progression of malignant tumors (25,26). Since VEGF-A is the most important
angiogenesis factor, the inhibition of VEGF-A production by cetuximab has the potential to inhibit angiogenesis in malignant tumors, leading to increased anti-tumor effects. In particular, in the absence of mediation by EGFR, cetuximab may be effective against EGFR-negative endometrial cancers.

Further, in animal experiments, cetuximab not only inhibited subcutaneous HEC1A tumor growth, but also peritoneal dissemination with ascites, and lymph node and lung metastasis in a model of extraterine extension, which is a negative prognostic factor in endometrial cancer. In addition, cetuximab prolonged the survival of the systemic metastasis mouse model. These results suggest the usefulness of cetuximab in the treatment of advanced or recurrent endometrial cancer.

Few studies of molecular-targeted therapy for endometrial cancer have been reported. Molecular-targeted therapy with cetuximab for endometrial cancer, which we propose here, could be advantageous for patients with advanced or recurrent endometrial cancer, in which the prognosis has not improved for the past 30 years due to the failure to develop new treatments.

References